Literature DB >> 33611347

Diving into Inflammation: A Pilot Study Exploring the Dynamics of the Immune-Microbiota Axis in Ileal Tissue Layers of Patients with Crohn's Disease.

Edda Russo1, Francesco Giudici1, Federica Ricci2, Stefano Scaringi1, Giulia Nannini1, Ferdinando Ficari1, Cristina Luceri3, Elena Niccolai1, Simone Baldi1, Mario D'Ambrosio3, Matteo Ramazzotti4, Amedeo Amedei1.   

Abstract

BACKGROUND AND AIMS: The pathogenesis of Crohn's disease [CD] is still unclear. Disorders in the mucosal immunoregulation and its crosstalk with the microbiota may represent an important component in tissue injury. We aimed to characterize the molecular immune response distribution within the ileal layers and to evaluate the correlated microbiota in pathological/healthy settings comparing first surgery/relapse clinical conditions.
METHODS: We enrolled 12 CD patients. A comprehensive analysis of an ileal mucosa, submucosa and serosa broad-spectrum cytokine panel was performed through a multiplex approach. In addition, ileal microbiota composition was assessed through next generation sequencing.
RESULTS: We observed a distinct profile [of IL1-α, IL-1β, IL-4, IL-8, ICAM-1, E-Selectin, P-Selectin, IP-10, IL 6 and IL 18] across the CD vs healthy ileal layers; and a different distribution of IFN- γ, P-Selectin, IL-27 and IL-21 in first surgery vs relapse patients. In addition, the phylum Tenericutes, the family Ruminococcaceae, and the genera Mesoplasma and Mycoplasma were significantly enriched in the pathological setting. Significant microbiota differences were observed between relapse and first surgery patients regarding the class Bacteroidia, and the genera Prevotella, Flavobacterium, Tepidimonas and Escherichia/Shigella. Finally, the abundance of the genus Mycoplasma was positively correlated with IL-18.
CONCLUSIONS: We describe a dissimilarity of cytokine distribution and microbiota composition within CD and adjacent healthy ileal tissue layers and between first operation and surgical relapse. Our results give potential insight into the dynamics of the gut microbiota-immune axis in CD patients, leading to detection of new biomarkers.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; cytokines; microbiota

Mesh:

Substances:

Year:  2021        PMID: 33611347     DOI: 10.1093/ecco-jcc/jjab034

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  9 in total

1.  Fecal microbiome in systemic sclerosis, in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control.

Authors:  Elisa Fiorentini; Edda Russo; Amedeo Amedei; Silvia Bellando Randone
Journal:  J Scleroderma Relat Disord       Date:  2022-09-25

2.  Eubacterium rectale Attenuates HSV-1 Induced Systemic Inflammation in Mice by Inhibiting CD83.

Authors:  S M Shamsul Islam; Hye-Myung Ryu; Hasan M Sayeed; Hae-Ok Byun; Ju-Yang Jung; Hyoun-Ah Kim; Chang-Hee Suh; Seonghyang Sohn
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 7.561

Review 3.  Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?

Authors:  Amedeo Amedei; Clemente Capasso; Giulia Nannini; Claudiu T Supuran
Journal:  Mediators Inflamm       Date:  2021-11-11       Impact factor: 4.711

4.  Gut Microbiome Alterations Affect Glioma Development and Foxp3 Expression in Tumor Microenvironment in Mice.

Authors:  Yiqi Fan; Qing Su; Junxiao Chen; Yong Wang; Shuai He
Journal:  Front Oncol       Date:  2022-03-08       Impact factor: 6.244

5.  Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.

Authors:  Edda Russo; Giulia Nannini; Gaetana Sterrantino; Seble Tekle Kiros; Vincenzo Di Pilato; Marco Coppi; Simone Baldi; Elena Niccolai; Federica Ricci; Matteo Ramazzotti; Marco Pallecchi; Filippo Lagi; Gian Maria Rossolini; Alessandro Bartoloni; Gianluca Bartolucci; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2022-02-14       Impact factor: 5.374

6.  Crohn's disease recurrence updates: first surgery vs. surgical relapse patients display different profiles of ileal microbiota and systemic microbial-associated inflammatory factors.

Authors:  Edda Russo; Lorenzo Cinci; Leandro Di Gloria; Simone Baldi; Mario D'Ambrosio; Giulia Nannini; Elisabetta Bigagli; Lavinia Curini; Marco Pallecchi; Donato Andrea Arcese; Stefano Scaringi; Cecilia Malentacchi; Gianluca Bartolucci; Matteo Ramazzotti; Cristina Luceri; Amedeo Amedei; Francesco Giudici
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

Review 7.  Impact of microbiota-immunity axis in pancreatic cancer management.

Authors:  Ilenia Bartolini; Giulia Nannini; Matteo Risaliti; Francesco Matarazzo; Luca Moraldi; Maria Novella Ringressi; Antonio Taddei; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

Review 8.  Inflammatory Bowel Disease and Customized Nutritional Intervention Focusing on Gut Microbiome Balance.

Authors:  Camilla Fiorindi; Edda Russo; Lucrezia Balocchini; Amedeo Amedei; Francesco Giudici
Journal:  Nutrients       Date:  2022-10-03       Impact factor: 6.706

9.  Characterization of the "gut microbiota-immunity axis" and microbial lipid metabolites in atrophic and potential celiac disease.

Authors:  Ricci Federica; Russo Edda; Renzi Daniela; Baldi Simone; Nannini Giulia; Lami Gabriele; Menicatti Marta; Pallecchi Marco; Bartolucci Gianluca; Niccolai Elena; Cerboneschi Matteo; Smeazzetto Serena; Ramazzotti Matteo; Amedei Amedeo; Calabrò Antonino Salvatore
Journal:  Front Microbiol       Date:  2022-09-30       Impact factor: 6.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.